Medtech Trends 2026: Strategic Implications for Eurasia's Industrial and Trade Evolution

Executive Summary

The medical technology (medtech) landscape is entering a period of accelerated change, driven by pricing reforms in major markets, shifting care delivery models, supply chain vulnerabilities, and the growing importance of enabling digital technologies. While these forces are global, their impact on Eurasia is distinct. As the region deepens its economic integration and seeks to position itself in advanced manufacturing and digital health, medtech trends are set to influence investment decisions, trade corridors, and industrial policy across the EU, Central Asia, and the Caucasus. This article explores the five pivotal medtech trends for 2026 and their strategic implications for the wider Eurasian business environment.

Introduction

The medtech sector has long been a bellwether for broader economic and technological shifts. In 2026, the sector is being reshaped by powerful structural forces: China's expanding volume-based procurement (VBP), the global migration of procedures to outpatient settings, persistent supply chain pressures, the metabolic health revolution, and the rise of platform-centric competition. For Eurasia, these trends are not abstract global developments. They are already influencing trade flows, foreign direct investment (FDI) patterns, and regional cooperation initiatives from the Middle Corridor to the European Single Market. Understanding these dynamics offers investors and policymakers a clearer view of how the region's industrial and logistical architecture will evolve over the next five years.

Main Analysis

1. Mainland China's VBP Expansion: Redefining Market Economics Across Eurasia

Mainland China's latest national volume-based procurement (VBP) rounds represent one of the most consequential shifts in global medtech pricing. Originally introduced to expand patient access and control costs, VBP has evolved into a sophisticated mechanism that anchors prices, compresses margins, and allocates market share in ways that favor domestic manufacturers. This has implications well beyond China's borders.

For Eurasian markets, particularly those along China's Belt and Road Initiative (BRI) corridors, VBP pressures are leading to an influx of lower-priced Chinese medical devices into Central Asian and Caucasus health systems. Countries like Kazakhstan, Uzbekistan, and Georgia have increasingly relied on Chinese imports for cost-effective healthcare solutions. However, this dynamic also raises concerns about quality assurance and long-term supply dependencies.

European medtech companies, many of which have historically exported to China, now face a strategic dilemma. As VBP suppresses prices and prioritizes local competitors, these firms may redirect exports toward emerging markets in Eastern Europe, the Western Balkans, and Türkiye. This could strengthen regional medical infrastructure but also intensify competition among European suppliers.

From an investment perspective, China's VBP policy is prompting multinational companies to reconsider their manufacturing footprints in Eurasia. Some are exploring joint ventures or local production in central or Eastern Europe to maintain access to Asian markets while mitigating tariff and procurement risks.

Why it matters: VBP is not merely a Chinese policy matter. It is accelerating the reorientation of global medtech value chains, influencing price expectations in developing markets, shaping trade flows along Eurasian corridors, and driving industrial strategies in both China and Europe.

2. Outpatient and Ambulatory Care Expansion: A Catalyst for Regional Infrastructure Investment

The global shift of procedures from hospitals to outpatient and ambulatory surgical centers (ASCs) is reshaping demand for medical technologies. In the United States, regulatory changes have expanded the range of procedures eligible for ASCs, including cardiac ablation and orthopedic surgeries. Similar trends are visible in Western Europe, where governments seek to reduce hospital costs and increase healthcare efficiency. In Eurasia's developing economies, the expansion of outpatient care is tied to broader modernization of healthcare infrastructure.

For regional governments in Central Asia and the Caucasus, this trend underlines the need to build ambulatory surgical facilities, diagnostic centers, and specialized outpatient clinics. Such investments align with national health reforms and create new opportunities for FDI and public-private partnerships (PPPs).

Medtech manufacturers serving Eurasian markets must adapt their commercial models to the needs of ASCs, which often prioritize compact devices, usability, and cost efficiency. This shift could encourage the local assembly or production of such equipment, particularly in countries with strong engineering traditions, such as Türkiye, Poland, and the Baltic states.

Why it matters: The transition to outpatient care opens a new chapter in healthcare infrastructure investment across Eurasia, linking health policy with industrial development and cross-border service trade.

3. Global Supply Chain Pressures: Reshaping Eurasian Manufacturing and Logistics

The medtech industry is confronting severe supply chain tensions as tariffs, geopolitical conflicts, and material costs disrupt long-established production networks. Many multinationals are now diversifying manufacturing locations and investing in more flexible, multi-regional footprints. This has important implications for Eurasia, which stands to benefit from both near-shoring and friend-shoring trends.

Countries in the Western Balkans, CeE, and the Caucasus are actively courting medtech manufacturers seeking to reduce reliance on East Asian production and enhance proximity to EU markets. Industrial parks in Serbia, Romania, and Georgia are being positioned as alternatives for device assembly, packaging, and distribution.

However, supply chain resilience in Central Asia is constrained by infrastructure gaps and dependence on a limited number of trade routes, notably the Trans-Caspian International Transport Route (Middle Corridor). The development of this corridor is becoming crucial not only for traditional cargo but also for time-sensitive medical logistics requiring cold-chain integrity.

Medtech companies are investing in regional distribution centers in hubs like Istanbul, Tbilisi, and Almaty to support cross-border flows. Governments, in turn, are upgrading customs and border infrastructure to facilitate the efficient movement of high-tech goods.

Why it matters: As supply chains are realigned, Eurasian countries that can provide reliable, high-quality manufacturing environments and secure logistics will attract strategic investment in the growing medtech sector.

4. GLP-1 Therapies: Shifting Patient Behavior and Affecting Pharmaceutical and Industrial Portfolios

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1s) for weight management and metabolic conditions is revolutionising care pathways globally. While bariatric surgery remains the most effective intervention for substantial weight loss, the availability of GLP-1 drugs has changed referral patterns and reduced demand for certain procedures. These shifts extend to adjacent markets, including diagnostics, cardiac monitoring, and sleep apnea devices.

In the EU, health systems are grappling with the budget impact of these therapies, which could affect reimbursement policies and technology assessments. In Central Asia and the Caucasus, pharmaceutical accessibility remains a challenge, yet new distribution routes and trade agreements may improve access over time.

For regional medtech and pharmaceutical players, GLP-1s present both opportunities and threats. Device makers focused on metabolic or obesity-related interventions may face lower procedure volumes. Conversely, the growing emphasis on preventive health could spur investment in digital health platforms and home monitoring tools.

Why it matters: The GLP-1 effect illustrates how pharmaceutical innovations can disrupt medtech markets, prompting Eurasia's health sectors to adjust strategic planning and investment priorities.

5. Enabling Technologies: Platform-Based Competition Requires Advanced Digital Infrastructure

Medtech is increasingly defined by enabling technologies—robotics, imaging, navigation, and digital workflow software—that form integrated platforms supporting clinical planning, surgery, and post-operative care. Companies are investing heavily in these platforms to create ecosystems that anchor customer relationships and generate data-driven value.

Across Eurasia, the expansion of digital infrastructure is a strategic priority from the EU's digital single market to Central Asia's adoption of smart technologies. Investments in cloud computing, data centers, and high-speed connectivity are laying the groundwork for advanced medtech platforms to reach underserved regions.

Cross-border data flows are a contentious issue, however, as regulations such as GDPR in Europe and evolving data sovereignty laws in Asia create friction. Harmonizing digital standards and fostering open platforms will be key to enabling seamless medical data sharing crucial for artificial intelligence models.

Eurasian economies that invest in robust digital ecosystems and skilled talent can position themselves as hubs for medical software development, telemedicine, and AI-assisted diagnostics. This is especially relevant for countries like Estonia, already a leader in digital health, which demonstrates the region's potential.

Why it matters: Platform-based competition underscores the importance of digital readiness, education, and cross-border regulatory alignment in determining the future competitiveness of Eurasian medtech players.

Business Impact

The medtech trends outlined above directly influence business competitiveness, investment decisions, and supply chain strategies across Eurasia. For corporations, the shifts signal the need for agility in navigating price pressures, adapting portfolios to outpatient and digital care models, and building resilient multi-regional manufacturing footprints.

• Corporate Strategy: Companies must reassess their product portfolios and market entry approaches as China's VBP and similar procurement initiatives become widespread in other Eurasian markets.
• Investment: FDI flows are likely to increase toward countries providing favorable conditions for health technology innovation and manufacturing, including EU accession candidates and Central Asian economies.
• Supply Chains: The development of regional logistics hubs will be essential, creating opportunities for logistics providers and infrastructure investors.
• Digital Economy: Investments in telemedicine and AI diagnostics align with broader regional digitalization objectives, supporting economic diversification.

Regional Perspective

The trends affect various Eurasian subregions differently:

• European Union: Faces regulatory and competitive pressure from lower-cost producers, but remains a leader in high-value medical devices and digital health ecosystems.
• Central Asia: Seeks to modernize health infrastructure, with Chinese and Turkish partners playing an influential role in supplying affordable devices and building outpatient facilities.
• Caucasus and Türkiye: Türkiye is emerging as a medtech manufacturing and export hub, leveraging its customs union with the EU and strong industrial base. The Caucasus benefits from trade corridor diversification.
• Eastern Europe and Western Balkans: Countries with established industrial heritage are attracting nearshoring investments in medical devices, supported by EU funds and competitive labor costs.
• Caspian Region: Energy-rich states are investing in health and medical infrastructure as part of their economic diversification plans.

Future Outlook

Looking to 2026 and beyond, the medtech sector in Eurasia will be shaped by further integration of digital technologies, evolving trade agreements, and geopolitical realignments. Over the next 3–5 years, our expectations include:

• Regional production capacities in Central Europe and Türkiye will expand, driven by tariff concerns and proximity to markets.
• The Middle Corridor will gain significance as a freight route for high-value medical goods, necessitating investment in temperature-controlled logistics.
• Policy harmonization in digital health, if achieved, will unlock cross-border telemedicine markets and accelerate AI adoption.
• China's export-oriented medtech will continue to influence Central Asian and Caucasus health procurement, prompting local quality and standards refinement.
• As GLP-1 and related therapies alter care pathways, medtech companies will pivot towards chronic disease monitoring and digital therapeutics, creating new partnerships with technology firms.

Conclusion

The medtech trends of 2026 are not isolated phenomena; they are integral to the broader transformation of Eurasia's economy. For governments and businesses, understanding these dynamics is crucial to seizing opportunities and mitigating risks. As the region strengthens its role in global production and trade, the medical technology sector offers a lens into the future of complex supply chains, digital integration, and human-centric innovation. Strategic investment in healthcare infrastructure, manufacturing capacity, and digital skills will determine which Eurasian economies emerge as winners in the evolving global health landscape.